Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444 is registered in ClinicalTrials.gov with Guardant Health, Inc. as lead sponsor.

NCT NCT05059444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05059444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Lead sponsor
Guardant Health, Inc.
Phase
Observational
Overall status
Recruiting
Start date
September 7, 2021
Completion date
August 31, 2030
Enrollment
2,285 (estimated)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

bladder carcinoma, colon adenocarcinoma, cutaneous melanoma, endometrial carcinoma, epithelial ovarian carcinoma, esophageal carcinoma, fallopian tube carcinoma, gastric adenocarcinoma, gastroesophageal junction carcinoma, invasive breast carcinoma, non-small cell lung cancer, pancreatic adenocarcinoma, rectal adenocarcinoma, renal cell carcinoma, renal pelvis carcinoma, squamous cell carcinoma of the head and neck, ureter carcinoma